AspirinPlatelet Aggregation InhibitorsRegistriesAnti-Inflammatory Agents, Non-SteroidalSwedenTiclopidineThromboxane B2Cyclooxygenase InhibitorsPlatelet AggregationDenmarkSalicylatesPlatelet Function TestsRisk FactorsRandomized Controlled Trials as TopicDrug Therapy, CombinationFinlandTreatment OutcomeIncidenceBlood PlateletsFibrinolytic AgentsSodium SalicylateCohort StudiesTime FactorsFollow-Up StudiesStrokeAnticoagulantsProspective StudiesHemorrhageAsthma, Aspirin-InducedWarfarinTablets, Enteric-CoatedGastrointestinal HemorrhageCyclooxygenase 1Myocardial InfarctionBleeding TimeDouble-Blind MethodGreat BritainProstaglandin-Endoperoxide SynthasesPlatelet ActivationThromboxanesDose-Response Relationship, DrugIbuprofenThromboxane A2Risk AssessmentEnglandThrombosisCyclooxygenase 2 InhibitorsPregnancyRiskDipyridamoleNorwaySex FactorsAge FactorsCardiovascular DiseasesNetherlandsCerebrovascular DisordersLipoxinsAcetaminophenDrug ResistanceIndomethacinResearch DesignOdds RatioPrimary PreventionSulfinpyrazoneRecurrenceInfant, NewbornEquipment SafetyGastric MucosaRetrospective StudiesCyclooxygenase 2QuestionnairesReye SyndromeStomach UlcerProstaglandinsProportional Hazards ModelsNaproxenCase-Control Studies